Return to Today's science sparks archives

2012-10-01

Summary of canonical and splicing-mediated miRNA pathways.

Summary of canonical and splicing-mediated miRNA pathways.
  • Ladewig E, Okamura K, Flynt AS, Westholm JO, Lai EC

  • Genome Res. 2012 Sep;22(9):1634-45.

2012-10-02

Fig 1a. GLV-1h153 infects, replicates within, and shows oncolytic activity against multiple TNBC cells in a dose-and time-dependent fashion in culture. Viral infection in a representative cell line, MDA-MB-231, is time dependent.

Fig 1a. GLV-1h153 infects, replicates within, and shows oncolytic activity against multiple TNBC cells in a dose-and time-dependent fashion in culture. Viral infection in a representative cell line, MDA-MB-231, is time dependent.
  • Gholami S, Chen CH, Lou E, De Brot M, Fujisawa S, Chen NG, Szalay AA, Fong Y

  • Ann Surg. 2012 Sep;256(3):437-445.

2012-10-03

Fig 1. Urine was fractionated by cation exchange chromatography and fractions containing immunoreactive neutrophil gelatinase–associated lipocalin (NGAL) species were then separated by filtration chromatography (left panels).

Fig 1. Urine was fractionated by cation exchange chromatography and fractions containing immunoreactive neutrophil gelatinase–associated lipocalin (NGAL) species were then separated by filtration chromatography (left panels).
  • Nickolas TL, Forster CS, Sise ME, Barasch N, Solá-Del Valle D, Viltard M, Buchen C, Kupferman S, Carnevali ML, Bennett M, Mattei S, Bovino A, Argentiero L, Magnano A, Devarajan P, Mori K, Erdjument-Bromage H, Tempst P, Allegri L, Barasch J

  • Kidney International (2012) 82, 718–722.

2012-10-04

Fig 3. Distribution of electroretinograms (ERGs) before ophthalmic artery chemosurgery and change (>25 µV) in ERGs after ophthalmic artery chemosurgery.

Fig 3. Distribution of electroretinograms (ERGs) before ophthalmic artery chemosurgery and change (>25 µV) in ERGs after ophthalmic artery chemosurgery.
  • Palioura S, Gobin YP, Brodie SE, Marr BP, Dunkel IJ, Abramson DH

  • Pediatr Blood Cancer. 2012 Nov;59(5):859-64.

2012-10-05

Fig 2. Sparse regression models predict differential expression of held-out genes and subtypes of tumor samples.

Fig 2. Sparse regression models predict differential expression of held-out genes and subtypes of tumor samples.
  • Setty M, Helmy K, Khan AA, Silber J, Arvey A, Neezen F, Agius P, Huse JT, Holland EC, Leslie CS

  • Mol Syst Biol. 2012 Aug 28;8:605.
Open Access button

2012-10-08

Fig 15.1. Phase II trial of tanespimycin and trastuzumab in metastatic trastuzumab-refractory HER2 positive breast cancer.

Fig 15.1. Phase II trial of tanespimycin and trastuzumab in metastatic trastuzumab-refractory HER2 positive breast cancer.
  • Jhaveri K, Modi S

  • Adv Pharmacol. 2012;65:471-517.

2012-10-09

Fig 3. Sclerosing Spitz nevus with epithelioid melanocytes adjacent to a lymphocytic aggregate.

Fig 3. Sclerosing Spitz nevus with epithelioid melanocytes adjacent to a lymphocytic aggregate.
  • Kiuru M, Patel RM, Busam KJ

  • J Cutan Pathol. 2012 Oct;39(10):940-4.

2012-10-10

Fig 2a. Stage-dependent effects of Dynein on muscle length and myonuclear positioning.

Fig 2a. Stage-dependent effects of Dynein on muscle length and myonuclear positioning.
  • Folker ES, Schulman VK, Baylies MK

  • Development. 2012 Oct;139(20):3827-37.

2012-10-11

Fig 2. Kaplan–Meier curve for overall survival in patients with advanced stage (IIIB/IV) disease.

Fig 2. Kaplan–Meier curve for overall survival in patients with advanced stage (IIIB/IV) disease.
  • Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, Paik PK, Zakowski MF, Kris MG, Ladanyi M

  • Clin Cancer Res. 2012 Sep 15;18(18):4910-8.

2012-10-12

Fig 3. Analysis of Olig2::Egfp-L10a translational profiles in normal brains and tumors identifies candidates for differentiation and quiescence of OPCs.

Fig 3. Analysis of Olig2::Egfp-L10a translational profiles in normal brains and tumors identifies candidates for differentiation and quiescence of OPCs.
  • Dougherty JD, Fomchenko EI, Akuffo AA, Schmidt E, Helmy KY, Bazzoli E, Brennan CW, Holland EC, Milosevic A

  • Cancer Res. 2012 Sep 15;72(18):4856-68.

2012-10-15

Fig 4. Effects on cancer cell viability and proliferation.

Fig 4. Effects on cancer cell viability and proliferation.
  • Augustsson P, Magnusson C, Nordin M, Lilja H, Laurell T

  • Anal Chem. 2012 Sep 18;84(18):7954-62.

2012-10-16

Fig 1a. Image of a high grade undifferentiated uterine sarcomas demonstrating features of endometrial stromal differentiation but a high mitotic rate and severe nuclear atypia.

Fig 1a. Image of a high grade undifferentiated uterine sarcomas demonstrating features of endometrial stromal differentiation but a high mitotic rate and severe nuclear atypia.
  • Tanner EJ, Garg K, Leitao MM Jr, Soslow RA, Hensley ML

  • Gynecol Oncol. 2012 Oct;127(1):27-31.

2012-10-17

Fig 1. Axial views at central axis (below) and 6 cm superior to central axis (above) showing isodose lines from representative left-sided treatment plans of patients without reconstruction (UNR) and with reconstruction (REC) with and without internal mammary node (IMN) treatment.

Fig 1. Axial views at central axis (below) and 6 cm superior to central axis (above) showing isodose lines from representative left-sided treatment plans of patients without reconstruction (UNR) and with reconstruction (REC) with and without internal mammary node (IMN) treatment.
  • Ohri N, Cordeiro PG, Keam J, Ballangrud A, Shi W, Zhang Z, Nerbun CT, Woch KM, Stein NF, Zhou Y, McCormick B, Powell SN, Ho AY

  • Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):e153-9.

2012-10-18

Fig 1. At the indicated time points, total numbers and frequencies of CD4+ Foxp3+ Tregs were determined by flow cytometry in LALs (A) and splenocytes (B).

Fig 1. At the indicated time points, total numbers and frequencies of CD4+ Foxp3+ Tregs were determined by flow cytometry in LALs (A) and splenocytes (B).
  • Stross L, Günther J, Gasteiger G, Asen T, Graf S, Aichler M, Esposito I, Busch DH, Knolle P, Sparwasser T, Protzer U

  • Hepatology. 2012 Sep;56(3):873-83.

2012-10-19

Fig 1b. GBM is a heterogeneous tumor composed of multiple cell types, including both tumor and stromal cells.

Fig 1b. GBM is a heterogeneous tumor composed of multiple cell types, including both tumor and stromal cells.
  • Helmy K, Halliday J, Fomchenko E, Setty M, Pitter K, Hafemeister C, Holland EC

  • PLoS One. 2012;7(10):e46965.
Open Access button

2012-10-22

Fig 2. Time spent hospitalized as percent of survival of the oldest PCNSL patients.

Fig 2. Time spent hospitalized as percent of survival of the oldest PCNSL patients.
  • Welch MR, Omuro A, Deangelis LM

  • Neuro Oncol. 2012 Oct;14(10):1304-11.

2012-10-23

Fig 3. Percentage of trials recommending each dose level based on simulated trials comparing 3+3 with CRM under type A and B errors.

Fig 3. Percentage of trials recommending each dose level based on simulated trials comparing 3+3 with CRM under type A and B errors.
  • Iasonos A, Gounder M, Spriggs DR, Gerecitano JF, Hyman DM, Zohar S, O'Quigley J

  • Clin Cancer Res. 2012 Oct 1;18(19):5179-87.

2012-10-24

Fig 5. Synergy between 4-OH-OPB and known TB drugs in killing Mtb.

Fig 5. Synergy between 4-OH-OPB and known TB drugs in killing Mtb.
  • Gold B, Pingle M, Brickner SJ, Shah N, Roberts J, Rundell M, Bracken WC, Warrier T, Somersan S, Venugopal A, Darby C, Jiang X, Warren JD, Fernandez J, Ouerfelli O, Nuermberger EL, Cunningham-Bussel A, Rath P, Chidawanyika T, Deng H, Realubit R, Glickman JF, Nathan CF

  • Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16004-11.
Open Access button

2012-10-25

Fig 1. Sample isodose curves of dose-painting intensity modulated radiation therapy (DP-IMRT) and sequential IMRT plans for 3-year-old patient with pelvic rhabdomyosarcoma (axial and coronal planes).

Fig 1. Sample isodose curves of dose-painting intensity modulated radiation therapy (DP-IMRT) and sequential IMRT plans for 3-year-old patient with pelvic rhabdomyosarcoma (axial and coronal planes).
  • Yang JC, Dharmarajan KV, Wexler LH, La Quaglia MP, Happersett L, Wolden SL

  • Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e371-7.

2012-10-26

Fig 5. Microenvironmental features within tissue sections of FaDu tumors at early and late time points postinjection of copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone).

Fig 5. Microenvironmental features within tissue sections of FaDu tumors at early and late time points postinjection of copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone).
  • McCall KC, Humm JL, Bartlett R, Reese M, Carlin S

  • Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e393-9.

2012-10-29

Fig 1. Chemical structures of the GSI BMS-708,163 and the inhibitor-based photoaffinity probe 163-BPyne used in this study.

Fig 1. Chemical structures of the GSI BMS-708,163 and the inhibitor-based photoaffinity probe 163-BPyne used in this study.
  • Crump CJ, Castro SV, Wang F, Pozdnyakov N, Ballard TE, Sisodia SS, Bales KR, Johnson DS, Li YM

  • Biochemistry. 2012 Sep 18;51(37):7209-11.

2012-10-30

Fig 2a. SET-2 and SET-2 INPer cells were washed and incubated for 4 h with increasing concentrations of INCB18424 and western blotted. MAPK, mitogen-activated protein kinase.

Fig 2a. SET-2 and SET-2 INPer cells were washed and incubated for 4 h with increasing concentrations of INCB18424 and western blotted. MAPK, mitogen-activated protein kinase.
  • Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL

  • Nature. 2012 Sep 6;489(7414):155-9.

2012-10-31

Fig 4(C2). Growth inhibition of TPC-1 cells and tumors by AZD1480 is independent of activated phospho-STAT3 Tyr705.

Fig 4(C2). Growth inhibition of TPC-1 cells and tumors by AZD1480 is independent of activated phospho-STAT3 Tyr705.
  • Couto JP, Almeida A, Daly L, Sobrinho-Simões M, Bromberg JF, Soares P

  • PLoS One. 2012;7(10):e46869.
Open Access button

2012-11-01

Fig 1. Brain MRI demonstrates a well-circumscribed, T1- and T2-isointense, contrast-enhancing lesion at the craniocervical junction.

Fig 1. Brain MRI demonstrates a well-circumscribed, T1- and T2-isointense, contrast-enhancing lesion at the craniocervical junction.
  • Strom RG, Shvartsbeyn M, Rosenblum MK, Hameed MR, Nafa K, Mikolaenko I, Babu RP

  • Clin Neurol Neurosurg. 2012 Oct;114(8):1197-200.

2012-11-02

Fig 6. A model of U1 snRNP-mediated p14 suppression.

Fig 6. A model of U1 snRNP-mediated p14 suppression.
  • Langemeier J, Schrom EM, Rabner A, Radtke M, Zychlinski D, Saborowski A, Bohn G, Mandel-Gutfreund Y, Bodem J, Klein C, Bohne J

  • EMBO J. 2012 Oct 17;31(20):4035-44.

2012-11-02

Fig 5. Fluorescence-guided, stepwise resection of an RCAS-PDGF glioblastoma using IRDye 800CW-RGD peptide NIRF imaging

Fig 5. Fluorescence-guided, stepwise resection of an RCAS-PDGF glioblastoma using IRDye 800CW-RGD peptide NIRF imaging
  • Huang R, Vider J, Kovar JL, Olive DM, Mellinghoff IK, Mayer-Kuckuk P, Kircher MF, Blasberg RG

  • Clin Cancer Res. 2012 Oct 15;18(20):5731-40.

2012-11-05

Fig 2. 53bp1 is a haploinsufficient tumor suppressor in a glioma mouse model.

Fig 2. 53bp1 is a haploinsufficient tumor suppressor in a glioma mouse model.
  • Squatrito M, Vanoli F, Schultz N, Jasin M, Holland EC

  • Cancer Res. 2012 Oct 15;72(20):5250-60.

2012-11-06

Fig 4(A). Relative Priming of AML Determines Clinical Outcome.

Fig 4(A). Relative Priming of AML Determines Clinical Outcome.
  • Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG, Letai A

  • Cell. 2012 Oct 12;151(2):344-55.

2012-11-07

Fig 2. Structure of (ziv-)aflibercept. Fc, fragment, crystallizable region; IgG, immunoglobulin G; VEGFR, vascular endothelial growth factor receptor.

Fig 2. Structure of (ziv-)aflibercept. Fc, fragment, crystallizable region; IgG, immunoglobulin G; VEGFR, vascular endothelial growth factor receptor.
  • Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, Baldotto C, Bennouna J, Shepherd FA, Le-Guennec S, Rey A, Miller V, Thatcher N, Scagliotti G

  • J Clin Oncol. 2012 Oct 10;30(29):3640-7.

2012-11-08

Fig 1. VCAM-1 expressed in breast cancer cells mediates lung and bone metastasis by interacting with stromal leukocytes that express α4 integrin counterreceptors.

Fig 1. VCAM-1 expressed in breast cancer cells mediates lung and bone metastasis by interacting with stromal leukocytes that express α4 integrin counterreceptors.
  • Chen Q, Massagué J

  • Clin Cancer Res. 2012 Oct 15;18(20):5520-5.

2012-11-09

Figure 4a. The Exosome Central Channel Is Essential In Vivo.

Figure 4a. The Exosome Central Channel Is Essential In Vivo.
  • Wasmuth EV, Lima CD

  • Mol Cell. 2012 Oct 12;48(1):133-44.

2012-11-12

Fig 1. Gli3−/− hindlimbs develop polydactyly and severe AP patterning defects only in the anterior zeugopod and autopod.

Fig 1. Gli3−/− hindlimbs develop polydactyly and severe AP patterning defects only in the anterior zeugopod and autopod.
  • Bowers M, Eng L, Lao Z, Turnbull RK, Bao X, Riedel E, Mackem S, Joyner AL

  • Dev Biol. 2012 Oct 1;370(1):110-24.

2012-11-13

Fig 3a. Axial T2 weighted MRI image of the prostate gland at the level of the apex and with endorectal coil in situ.

Fig 3a. Axial T2 weighted MRI image of the prostate gland at the level of the apex and with endorectal coil in situ.
  • Riaz N, Afaq A, Akin O, Pei X, Kollmeier MA, Cox B, Hricak H, Zelefsky MJ

  • Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):707-11.

2012-11-14

Fig 2. Flow cytometric measurements of γH2AX in PB cells.

Fig 2. Flow cytometric measurements of γH2AX in PB cells.
  • Abd Elmoneim A, Gore L, Ricklis RM, Boklan J, Cooper T, Narendran A, Rolla K, Scott T, Arceci RJ

  • Pediatr Blood Cancer. 2012 Dec 15;59(7):1252-8.

2012-11-15

Fig 1. BEZ235 induces dose and time dependent cytotoxicity in 8 thyroid cancer cell lines.

Fig 1. BEZ235 induces dose and time dependent cytotoxicity in 8 thyroid cancer cell lines.
  • Lin SF, Huang YY, Lin JD, Chou TC, Hsueh C, Wong RJ

  • PLoS One. 2012;7(10):e46726.
Open Access button

2012-11-16

Fig 2. G arm quality of life sensitivity analysis.

Fig 2. G arm quality of life sensitivity analysis.
  • Phippen NT, Leath CA 3rd, Chino JP, Jewell EL, Havrilesky LJ, Barnett JC

  • Gynecol Oncol. 2012 Nov;127(2):267-72.

2012-11-19

Fig 4a. Heatmap of the nine-signature genes (annotated on the right) in the 94-patient samples assessed with TaqMan probes.

Fig 4a. Heatmap of the nine-signature genes (annotated on the right) in the 94-patient samples assessed with TaqMan probes.
  • Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G, Fleisher M, Reid AH, Castro E, Sandhu SK, Barwell L, Oommen NB, Carreira S, Drake CG, Jones R, Cooper CS, Scher HI, de Bono JS

  • Lancet Oncol. 2012 Nov;13(11):1114-24.

2012-11-20

Fig 1c. Changes in 5hmC and 5mC are associated with site-specific hypermethylation and transcriptional silencing in normal individuals with TET2 mutations, as measured by MassArray Epityper (left) and quantitative RT-PCR (qRT-PCR, right) analyses in the PMNs of six individuals with WT TET2 and six with mutant (mut) TET2.

Fig 1c. Changes in 5hmC and 5mC are associated with site-specific hypermethylation and transcriptional silencing in normal individuals with TET2 mutations, as measured by MassArray Epityper (left) and quantitative RT-PCR (qRT-PCR, right) analyses in the PMNs of six individuals with WT TET2 and six with mutant (mut) TET2.
  • Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, Mollica L, Li J, Viale A, Heguy A, Hassimi M, Socci N, Bhatt PK, Gonen M, Mason CE, Melnick A, Godley LA, Brennan CW, Abdel-Wahab O, Levine RL

  • Nat Genet. 2012 Nov;44(11):1179-81.

2012-11-21

Fig 1. Major capsular and vascular invasion with high mitotic activity confirming diagnosis of parathyroid carcinoma.

Fig 1. Major capsular and vascular invasion with high mitotic activity confirming diagnosis of parathyroid carcinoma.
  • Mohebati A, Shaha A, Shah J.

  • Hematol Oncol Clin North Am. 2012 Dec;26(6):1221-38.

2012-11-26

Fig 1. Number of sentinel lymph node biopsy-positive patients with omission of axillary lymph node dissection by year.

Fig 1. Number of sentinel lymph node biopsy-positive patients with omission of axillary lymph node dissection by year.
  • Milgrom S, Cody H, Tan L, Morrow M, Pesce C, Setton J, Rogers K, Arnold B, Eaton A, Catalano J, McCormick B, Powell S, Ho A

  • Ann Surg Oncol. 2012 Nov;19(12):3762-70.

2012-11-27

Fig 1e. Histopathologic correlate showing a cystic variant of a BCC with basaloid tumor cells arranged in nests. Areas of mucin deposition (white asterisk) can be observed surrounding the tumor islands and forming cystic spaces (black asterisk).

Fig 1e. Histopathologic correlate showing a cystic variant of a BCC with basaloid tumor cells arranged in nests. Areas of mucin deposition (white asterisk) can be observed surrounding the tumor islands and forming cystic spaces (black asterisk).
  • Ulrich M, Lange-Asschenfeldt S, González S

  • Actas Dermosifiliogr. 2012 Nov;103(9):784-9.

2012-11-28

Fig 1a. Representative full-transverse section of proximal jejunum from Lgr5-lacZ transgenic mice stained for lacZ. LacZ+ CBCs are visible at the crypt base (blue cells with arrow).

Fig 1a. Representative full-transverse section of proximal jejunum from Lgr5-lacZ transgenic mice stained for lacZ. LacZ+ CBCs are visible at the crypt base (blue cells with arrow).
  • Hua G, Thin TH, Feldman R, Haimovitz-Friedman A, Clevers H, Fuks Z, Kolesnick R

  • Gastroenterology. 2012 Nov;143(5):1266-76.

2012-11-29

Fig 5 . Visual predictive check (VPC) of 10,000 simulated patients (A) on placebo before their switch to everolimus.

Fig 5 . Visual predictive check (VPC) of 10,000 simulated patients (A) on placebo before their switch to everolimus.
  • Stein A, Wang W, Carter AA, Chiparus O, Hollaender N, Kim H, Motzer RJ, Sarr C.

  • BMC Cancer. 2012 Jul 23;12:311.
Open Access button

2012-11-30

Fig 7. Nodal knockdown mitigates progression to macrometastases. (B)GUSB staining to confirm human origin of lesions showing 231+shControl macrometastasis formation after 8 weeks.

Fig 7. Nodal knockdown mitigates progression to macrometastases. (B)GUSB staining to confirm human origin of lesions showing 231+shControl macrometastasis formation after 8 weeks.
  • Quail DF, Zhang G, Walsh LA, Siegers GM, Dieters-Castator DZ, Findlay SD, Broughton H, Putman DM, Hess DA, Postovit LM

  • PLoS One. 2012;7(11):e48237.
Open Access button

2012-12-03

Fig 2a. Confirmed maximum reduction in intracranial target lesion for patients with Val600Glu BRAF-mutant melanoma and brain metastases in cohort A.

Fig 2a. Confirmed maximum reduction in intracranial target lesion for patients with Val600Glu BRAF-mutant melanoma and brain metastases in cohort A.
  • Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D

  • Lancet Oncol. 2012 Nov;13(11):1087-95.

2012-12-04

Fig 2A.Changes in NTX over time relative to diagnosis of ONJ (restricted to patients with 3 or more blood draws; n = 33).

Fig 2A.Changes in NTX over time relative to diagnosis of ONJ (restricted to patients with 3 or more blood draws; n = 33).
  • Morris PG, Fazio M, Farooki A, Estilo C, Mallam D, Conlin A, Patil S, Fleisher M, Cremers S, Huryn J, Hudis CA, Fornier MN

  • J Oral Maxillofac Surg. 2012 Dec;70(12):2768-75.

2012-12-05

Fig 1. Breakdown of bone densitometry diagnoses at baseline and over the course of CC therapy (BD, bone density).

Fig 1. Breakdown of bone densitometry diagnoses at baseline and over the course of CC therapy (BD, bone density).
  • Moskovic DJ, Katz DJ, Akhavan A, Park K, Mulhall JP

  • BJU Int. 2012 Nov;110(10):1524-8.

2012-12-06

Fig. 2. Proposed strategy to incorporate perioperative systemic therapy for cisplatin-ineligible or refusing patients with urothelial carcinoma of the bladder (UCB).

Fig. 2. Proposed strategy to incorporate perioperative systemic therapy for cisplatin-ineligible or refusing patients with urothelial carcinoma of the bladder (UCB).
  • Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T, Sternberg CN, Sonpavde G

  • Eur Urol. 2012 Sep;62(3):523-33.

2012-12-07

Fig 1. Box-and-whisker plot of total hemoglobin concentration distribution in 136 malignant and benign lesions.

Fig 1. Box-and-whisker plot of total hemoglobin concentration distribution in 136 malignant and benign lesions.
  • Zhi W, Gu X, Qin J, Yin P, Sheng X, Gao SP, Li Q

  • Radiology. 2012 Nov;265(2):371-8.

2012-12-10

Fig 1. Trial design is depicted.

Fig 1. Trial design is depicted.
  • Beasley GM, Coleman AP, Raymond A, Sanders G, Selim MA, Peterson BL, Brady MS, Davies MA, Augustine C, Tyler DS

  • Ann Surg Oncol. 2012 Nov;19(12):3896-905.

2012-12-11

Fig 1. Forest plot of individual PanC4 studies—odds ratios (ORs) and 95% confidence intervals (CIs) for pancreatitis (diagnosed >2 years before) and risk of pancreatic cancer.

Fig 1. Forest plot of individual PanC4 studies—odds ratios (ORs) and 95% confidence intervals (CIs) for pancreatitis (diagnosed >2 years before) and risk of pancreatic cancer.
  • Duell EJ, Lucenteforte E, Olson SH, Bracci PM, Li D, Risch HA, Silverman DT, Ji BT, Gallinger S, Holly EA, Fontham EH, Maisonneuve P, Bueno-de-Mesquita HB, Ghadirian P, Kurtz RC, Ludwig E, Yu H, Lowenfels AB, Seminara D, Petersen GM, La Vecchia C, Boffetta P

  • Ann Oncol. 2012 Nov;23(11):2964-70.

2012-12-12

Fig 1a. Dose-volume histogram for the target volumes (PTV57.6) using whole-neck field IMRT (WF-IMRT) and junctioned IMRT (J-IMRT).

Fig 1a. Dose-volume histogram for the target volumes (PTV57.6) using whole-neck field IMRT (WF-IMRT) and junctioned IMRT (J-IMRT).
  • Bar Ad V, Lin H, Hwang WT, Deville C, Dutta PR, Tochner Z, Both S

  • Med Dosim. 2012 Winter;37(4):383-6.

2012-12-13

Fig 2b. Raman intensity maps of a single RAW 264.7 macrophage 32.4 min after introducing nanotubes.

Fig 2b. Raman intensity maps of a single RAW 264.7 macrophage 32.4 min after introducing nanotubes.
  • Kang JW, Nguyen FT, Lue N, Dasari RR, Heller DA

  • Nano Lett. 2012; 12(12): 6170–74.

2012-12-14

Fig 1a. Diagram of the calibration setup. The custom polystyrene phantom is shown with foil.

Fig 1a. Diagram of the calibration setup. The custom polystyrene phantom is shown with foil.
  • Folkert MR, Bilsky MH, Cohen GN, Zaider M, Dauer LT, Cox BW, Boland PJ, Laufer I, Yamada Y

  • Neurosurgery. 2012 Nov;71(5):1003-11.

2012-12-17

Fig 1. Average distances from parathyroid adenomas to the recurrent laryngeal nerve.

Fig 1. Average distances from parathyroid adenomas to the recurrent laryngeal nerve.
  • Untch BR, Adam MA, Danko ME, Barfield ME, Dixit D, Scheri RP, Olson JA

  • Ann Surg Oncol. 2012 Nov;19(12):3823-6.

2012-12-18

Fig 1. Various staging algorithms for localized gastric cancer and estimated associated costs.

Fig 1. Various staging algorithms for localized gastric cancer and estimated associated costs.
  • Smyth E, Schöder H, Strong VE, Capanu M, Kelsen DP, Coit DG, Shah MA

  • Cancer. 2012 Nov 15;118(22):5481-8.

2012-12-19

Fig 2. Disease free (A) and overall survival (B, C) with concurrent carboplatin/paclitaxel and intravaginal radiation for uterine papillary serous cancer (n = 41 patients).

Fig 2. Disease free (A) and overall survival (B, C) with concurrent carboplatin/paclitaxel and intravaginal radiation for uterine papillary serous cancer (n = 41 patients).
  • Kiess AP, Damast S, Makker V, Kollmeier MA, Gardner GJ, Aghajanian C, Abu-Rustum NR, Barakat RR, Alektiar KM

  • Gynecol Oncol. 2012 Nov;127(2):321-5

2012-12-20

Fig 3. Binding of 3F8BiAb to ATC and target cells.

Fig 3. Binding of 3F8BiAb to ATC and target cells.
  • Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NK, Lum LG

  • Pediatr Blood Cancer. 2012 Dec 15;59(7):1198-205.

2012-12-21

Fig 1a. Quantitative real-time PCR was used for the detection of miR-101 and COX-2 mRNA expression. In each sample, miR-101 expression was normalized against U6 RNA, and COX-2 mRNA expression was normalized against GAPDH mRNA.

Fig 1a. Quantitative real-time PCR was used for the detection of miR-101 and COX-2 mRNA expression. In each sample, miR-101 expression was normalized against U6 RNA, and COX-2 mRNA expression was normalized against GAPDH mRNA.
  • He XP, Shao Y, Li XL, Xu W, Chen GS, Sun HH, Xu HC, Xu X, Tang D, Zheng XF, Xue YP, Huang GC, Sun WH

  • FEBS J. 2012 Nov;279(22):4201-12.

2012-12-24

Fig 1. Urothelial carcinoma in situ with denudation.

Fig 1. Urothelial carcinoma in situ with denudation.
  • Amin MB, McKenney JK, Paner GP, Hansel DE, Grignon DJ, Montironi R, Lin O, Jorda M, Jenkins LC, Soloway M, Epstein JI, Reuter VE

  • Eur Urol. 2013 Jan;63(1):16-35.

2012-12-26

Fig 3. Disseminated intravascular coagulation (DIC) is common in patients with t(8;16) AML. Overall survival correlates with the degree of presenting fibrinogen levels (r2 = 0.90; data plotted for 8 patients only with available presenting fibrinogen level) (A) (all patients with DIC died, no censored patients).

Fig 3. Disseminated intravascular coagulation (DIC) is common in patients with t(8;16) AML. Overall survival correlates with the degree of presenting fibrinogen levels (r2 = 0.90; data plotted for 8 patients only with available presenting fibrinogen level) (A) (all patients with DIC died, no censored patients).
  • Diab A, Zickl L, Abdel-Wahab O, Jhanwar S, Gulam MA, Panageas KS, Patel JP, Jurcic J, Maslak P, Paietta E, Mangan JK, Carroll M, Fernandez HF, Teruya-Feldstein J, Luger SM, Douer D, Litzow MR, Lazarus HM, Rowe JM, Levine RL, Tallman MS

  • Leuk Res. 2013 Jan;37(1):32-6

2012-12-27

Fig 1: Large T antigen is not an obligate double hexamer during replication. A. Models for DNA unwinding by large T antigen (T-ag). See main text for details.

Fig 1: Large T antigen is not an obligate double hexamer during replication. A. Models for DNA unwinding by large T antigen (T-ag). See main text for details.
  • Yardimci H, Wang X, Loveland AB, Tappin I, Rudner DZ, Hurwitz J, van Oijen AM, Walter JC

  • Nature. 2012 Dec 13;492(7428):205-9.

2012-12-28

Fig 2. Enrichment of the Stem-like Tumorigenic Pool Based on EphA2 Level. (D) Cells from the same hGBM were sorted and gated according to EphA2 and SSEA-1 levels.

Fig 2. Enrichment of the Stem-like Tumorigenic Pool Based on EphA2 Level. (D) Cells from the same hGBM were sorted and gated according to EphA2 and SSEA-1 levels.
  • Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, Huse JT, Cajola L, Zanetti N, Dimeco F, De Filippis L, Mangiola A, Maira G, Anile C, De Bonis P, Reynolds BA, Pasquale EB, Vescovi AL

  • Cancer Cell. 2012 Dec 11;22(6):765-80.

2012-12-31

Fig 2. Architecture of Orai. (A) Ribbon representation showing the tertiary structure of the channel from the side.

Fig 2. Architecture of Orai. (A) Ribbon representation showing the tertiary structure of the channel from the side.
  • Hou X, Pedi L, Diver MM, Long SB

  • Science. 2012 Dec 7;338(6112):1308-13.